“New Drug Promises Better Treatment for Cancer Patients”
Daily Nation
In this article, Hellen Shikanda narrates the cancer journey of a patient named Alex, who was diagnosed with stage IV colon cancer that had metastasized to his liver and who benefited from a phase Ib trial of an experimental molecularly targeted therapeutic. After several difficult rounds of chemotherapy, genetic testing of Alex’s tumor revealed that his cancer had an alteration in the KRAS protein called KRASG12C. Fortunately, Alex was able to participate in a phase Ib clinical trial that was evaluating a KRASG12C-targeted therapeutic at Aga Khan University Hospital in Nairobi, Kenya. Shikanda’s story masterfully highlights the ongoing promise of molecularly targeted treatments such as these, which have been transformational for many patients and which continue to improve.
Read the Story